Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Boehringer Ingelheim
Astellas Pharma Inc
Merck Sharp & Dohme LLC
Amgen
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
Astellas Pharma Inc
ModernaTX, Inc.
Astellas Pharma Inc
Bristol-Myers Squibb
Isala
Vividion Therapeutics, Inc.
Erasca, Inc.
Eli Lilly and Company
University of California, San Diego
Wake Forest University Health Sciences
Rondo Therapeutics
Shenzhen Ionova Life Sciences Co., Ltd.
Vividion Therapeutics, Inc.
Dragonfly Therapeutics
Merck Sharp & Dohme LLC
QuantumLeap Healthcare Collaborative
NeoImmuneTech
Revolution Medicines, Inc.
Hoffmann-La Roche
University of Ulm
Amgen
Dana-Farber Cancer Institute
Children's Hospital Medical Center, Cincinnati
Tizona Therapeutics, Inc
Essen Biotech
Nouscom SRL
University of California, San Diego
Werewolf Therapeutics, Inc.
Hoffmann-La Roche
Teva Branded Pharmaceutical Products R&D, Inc.
Cytovation AS
University of California, San Diego
M.D. Anderson Cancer Center
Centre Leon Berard
Novartis
MediLink Therapeutics (Suzhou) Co., Ltd.
Riboscience, LLC.
Inhibrx Biosciences, Inc
GlaxoSmithKline
Sairopa B.V.
Synthorx, Inc, a Sanofi company
Memorial Sloan Kettering Cancer Center